Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PARAGON-HF: Novartis Hangs Onto Hope For Entresto In HFpEF

Executive Summary

Despite Phase III miss, Novartis is hopeful that the totality of the evidence will secure it at least a limited label expansion to a sizable but harder to treat portion of the heart failure market than Entresto already serves.

You may also be interested in...



Keeping Track: Submissions From Sanofi, Merck, Novartis; Breakthrough Designations For GSK And Takeda

The latest news of submissions and expedited review designations from the Pink Sheet’s US FDA Performance Tracker

The Medicines Company Rises On Novartis Takeover Rumors

It's been a good week for the US company with its PCSK9 gene-silencing drug impressing at the American Heart Association meeting and reports that Novartis is close to making a bid.

Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure

The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel